Evaluating dysarthria treatment in parkinson disease per patient, family and clinician: treatment implementation, barriers and facilitators, and outcomes and adherence

Active Grant Awarded

Award ID
R01DC023301
Recipient
Awarding agency
Obligated
$666,519

Award facts

Completion date 5% complete
Place of performance
Charleston, SC 29425, USA

Award details come from USAspending.gov.

About this award

The National Institute on Deafness and Other Communication Disorders, within the National Institutes of Health and the Department of Health and Human Services, awarded The Medical University of South Carolina a grant of $666,519 on August 17, 2026, under the Research Related to Deafness and Communication Disorders program (Assistance Listing 93.173). The award funds Grant R01DC023301, a pragmatic clinical trial that evaluates dysarthria treatment for Parkinson disease in routine clinical settings. The project examines treatment outcomes and adherence over time for a broad group of patients across various practice settings (Specific Aim 1). It also examines how therapy outcomes change in relation to patient, disease, and healthcare factors associated with treatment response. The project's stated purpose is to characterize patient outcomes and the contextual factors that affect treatment delivery in real-world clinical settings, where prior randomized trials of motor speech interventions were conducted under highly constrained conditions.

The recipient performs the work in Charleston, South Carolina (ZIP 29425). The period of performance runs from the August 17, 2026 award date to an ultimate completion date of July 31, 2031. The assistance type is grant.

Description

Abstract
Hypokinetic dysarthria, a motor speech disorder affecting approximately 90% of individuals with parkinson's disease (PD), is characterized by reduced speaking volume, imprecise articulation, impaired prosody, and decreased speech intelligibility. These speech and voice symptoms result in substantial communication difficulties, often leading to social isolation and diminished quality of life. Addressing these symptoms is a crucial component of motor speech interventions, aimed at improving communication and enhancing overall well-being for individuals with PD. While randomized controlled trials have reported on the efficacy of motor speech interventions for hypokinetic dysarthria in highly constrained environments, therapy outcomes and adherence have not been studied in dynamic clinical practice conditions. Real-life healthcare environments differ from clinical research trials in several key respects, including patient diversity, clinician training and experience, and the presence of organizational and structural barriers, such as resource availability, productivity demands, and policy constraints. Pragmatic clinical trials are specifically designed to bridge this GAP by evaluating how interventions perform in routine clinical environments. This project will employ a pragmatic clinical trial design to characterize patient outcomes and the contextual factors associated with treatment delivery in real-world clinical settings. Specifically, we will examine treatment outcomes and adherence over time for a broad group of patients with PD in various practice settings (specific aim 1). In addition, we will examine changes in therapy outcomes in the context of patient-, disease-, and healthcare factors in order to better understand the factors associated with treatment response (specific aim 2). This is an important first step in understanding which patients are most likely to benefit from specific therapy approaches, so we can improve clinical decision-making guidelines. Focus groups with patients and caregivers will explore perceived barriers and facilitators that influence treatment participation and adherence (specific aim 3). Finally, using clinician-reported survey and focus group data, we will identify the perceived barriers and facilitators to implementing evidence-based dysarthria interventions across diverse healthcare environments (specific aim 4). By identifying the patient, clinician, and system-level factors that influence treatment response and adherence, this research will inform the future development of scalable implementation strategies to enhance the reach, effectiveness, and long-term impact of dysarthria interventions across healthcare settings.

Subawards

Subrecipient Amount Awarded
University Of Washington Responsibilities of University of Washington site: Dr. Baylor at the University of Washington will be responsible for the qualitative branch of this project… $131,276

Quick answers

Who received award R01DC023301?

R01DC023301 was awarded to The Medical University Of South Carolina by National Institute on Deafness and Other Communincation Disorders (National Institutes of Health) on August 17, 2026.

How much is award R01DC023301 worth?

$666,519 has been obligated on R01DC023301.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award